ENTPD1 and cancer: In the context of cancer, increased expression and activity of CD39 and CD73 in tissues and/or biological fluids can lead to high levels of Ado that potently suppress the T cell-mediated antitumor immune response and promote tumor progression through stimulation of ARs [7, 41].